\Multi-Center Phase I Study of Avutometinib (VS-6766), a RAF/MEK Clamp in Combination With Defactinib, a FAK Inhibitor, in Pediatric Patients With Refractory or Recurrent Solid Tumors Harboring Activating MAPK Pathway or NF2 Alterations
This study is testing a new medication called avutometinib to see if it safely helps treat children and young adults with solid tumors that haven't responded to standard care. Researchers are working to find the best dose that stops cancer growth while keeping side effects as low as possible.
This study is for patients between 3 and 30 years old who have specific types of solid tumors or nerve-related growths with certain gene changes. Participants must also be well enough to carry out daily activities on their own.
Participants will receive the study medication to see how it affects their tumors and how their body handles it. Because this is a safety study, doctors will monitor participants very closely for any side effects throughout the process.
The study is currently active but not looking for new patients. It is being conducted at specialized medical centers in Atlanta, Georgia, and New York, New York.
- 1Tests a new medicine designed to block signals that help cancer cells grow.
- 2Focuses on young patients with tumors involving specific gene changes or nerve conditions like NF1.
- 3The primary goal is to determine a safe and effective dose for this medication.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.